| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 11% | 0% | 5,096,251 | 0% | Armistice Capital, LLC | 31 Dec 2025 |
As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Aridis Pharmaceuticals, Inc. - Common Stock (ARDS). This represents 0% of the company’s total 44,586,623 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$3 | 0 | |
| 2025 Q3 | 3,000 | $3 | +$3 | $0.00 | 1 |
| 2024 Q1 | 0 | $0 | -$10 | 0 | |
| 2023 Q4 | 150 | $10 | -$1,427 | $0.07 | 1 |
| 2023 Q3 | 14,077 | $1,437 | -$389,218 | $0.10 | 1 |
| 2023 Q2 | 1,783,583 | $392,314 | -$723,999 | $0.22 | 17 |
| 2023 Q1 | 4,126,564 | $1,294,359 | -$1,724,919 | $0.31 | 19 |
| 2022 Q4 | 3,883,903 | $4,581,334 | +$2,334,952 | $1.18 | 17 |
| 2022 Q3 | 1,926,605 | $1,791,233 | +$109,351 | $0.93 | 16 |
| 2022 Q2 | 1,868,871 | $2,053,275 | -$95,897 | $1.10 | 19 |
| 2022 Q1 | 1,920,976 | $3,377,440 | +$1,117,849 | $1.76 | 20 |
| 2021 Q4 | 1,269,305 | $2,956,583 | -$3,467,952 | $2.33 | 18 |
| 2021 Q3 | 1,991,394 | $7,327,920 | +$2,958,923 | $3.68 | 17 |
| 2021 Q2 | 1,077,025 | $7,869,850 | +$538,496 | $7.40 | 13 |
| 2021 Q1 | 1,011,836 | $5,967,000 | +$1,597,317 | $5.90 | 10 |
| 2020 Q4 | 741,213 | $4,500,518 | +$1,273,959 | $6.08 | 11 |
| 2020 Q3 | 182,604 | $1,292,770 | +$535,515 | $7.08 | 7 |
| 2020 Q2 | 107,034 | $710,658 | +$82,008 | $6.65 | 6 |
| 2020 Q1 | 95,330 | $550,000 | +$17,249 | $5.77 | 6 |
| 2019 Q4 | 92,497 | $411,000 | -$84,605 | $4.37 | 5 |
| 2019 Q3 | 111,016 | $745,000 | +$428,963 | $6.68 | 6 |
| 2019 Q2 | 46,980 | $477,000 | -$125,042 | $10.00 | 5 |
| 2019 Q1 | 58,379 | $642,000 | +$480,894 | $10.98 | 4 |
| 2018 Q4 | 14,596 | $161,000 | -$513,485 | $10.96 | 4 |
| 2018 Q3 | 55,667 | $725,000 | +$725,000 | $13.03 | 6 |